



PROVIDING ANSWERS FOR CANCER PATIENTS

Press release
December 16, 2020

Japanese patent application 2019-005811 is accepted for grant

The Japan Patent Office has issued a notice of allowance confirming that the Japanese Patent Application no. 2019-005811 regarding 177-Lu Labeled peptide conjugate for site specific uPAR-targeting will be granted.

This patent application relates to Curasight's therapeutic technology uTREAT® and uses thereof. More specifically the invention relates to human uPAR targeted radionuclide therapy, which enables local irradiation of cancer with almost no irradiation of healthy tissue. Together with uTRACE® the combination is known as uPAR Theranostics – the combination of **therapy** and **diagnostics**.

"The validation of this Japanese patent application has now been officially confirmed by the Japan Patent Office. For Curasight this is an important milestone in the development of uTREAT® as a therapeutic option in cancer" says CEO Ulrich Krasilnikoff.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology provides improved diagnosis and risk stratification in multiple cancer types.